A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous Antegren(TM) (Natalizumab) in Subjects With Moderately to Severely Active Crohn's Disease With Elevated C-Reactive Protein
收藏DataCite Commons2025-07-24 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00002835/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this trial is to evaluate natalizumab in individuals with moderately to severely active Crohn's Disease.
提供机构：
Vivli
创建时间：
2018-10-27
